Payment overview · 2025
General Payments
$248.94
12 reported records · 6 companies
Healthcare provider profile · identity verified
Randy Jackson Curl, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SHELL KNOB, MO · NPI 1326053208
Verified facts
What the public records show
CMS Open Payments records show Randy Jackson Curl, M.D. received $248.94 in general payments during 2025 across 12 reported records.
Lilly USA, LLC accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.28 | 23.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $52.46 | 21.1% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $40.13 | 16.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.97 | 14.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.85 | 14.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.25 | 10.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $248.94 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $52.46 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $40.13 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.85 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 379 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 87 |
| Lisinopril | Lisinopril | 284 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 246 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 63 |
| Losartan Potassium | Losartan Potassium | 206 | 60 |
| Omeprazole | Omeprazole | 203 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 183 | 104 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 182 | 84 |
| Potassium Chloride | Potassium Chloride | 178 | 47 |
| Prednisone | Prednisone | 169 | 124 |
| Gabapentin | Gabapentin | 161 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 50 |
| Furosemide | Furosemide | 146 | 54 |
| Alprazolam | Alprazolam | 139 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 44 |
| Meloxicam | Meloxicam | 131 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 116 | 109 |
| Montelukast Sodium | Montelukast Sodium | 114 | 24 |
| Tramadol Hcl | Tramadol Hcl | 112 | 48 |
| Metformin Hcl | Metformin Hcl | 111 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 31 |
| Simvastatin | Simvastatin | 102 | 36 |
| Methylprednisolone | Methylprednisolone | 100 | 95 |
| Famotidine | Famotidine | 97 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 27 |
| Clonazepam | Clonazepam | 95 | 20 |
| Carvedilol | Carvedilol | 87 | 26 |
| Sertraline Hcl | Sertraline Hcl | 87 | 21 |
| Allopurinol | Allopurinol | 81 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 81 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 22 |
| Trazodone Hcl | Trazodone Hcl | 74 | 24 |
| Azithromycin | Azithromycin | 73 | 60 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 17 |
| Ibuprofen | Ibuprofen | 67 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 26 |
| Eliquis | Apixaban | 63 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 56 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 52 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 46 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Lovastatin | Lovastatin | 51 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 39 |
| Finasteride | Finasteride | 50 | 15 |
| Baclofen | Baclofen | 49 | suppressed |
| Jardiance | Empagliflozin | 48 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Temazepam | Temazepam | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 44 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 11 |
| Alendronate Sodium | Alendronate Sodium | 41 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 39 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 11 |
| Farxiga | Dapagliflozin Propanediol | 36 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 14 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Atenolol | Atenolol | 33 | 11 |
| Cephalexin | Cephalexin | 33 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 11 |
| Metformin Hcl Er | Metformin Hcl | 31 | 11 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 17 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 13 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 23 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Nystatin | Nystatin | 14 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $248.94 · 12 records | Lilly USA, LLC | Auvelity, CAPLYTA, Cologuard Collection Kit, KISUNLA, MOUNJARO, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error